Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level

Hedvig Hricak, Heiko Schöder, Darko Pucar, Eric Lis, Steven C. Eberhardt, Chinyere N. Onyebuchi, Howard I. Scher

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's needs. There are evidence-based guidelines for the use of imaging in assessing the presence of distant spread of prostate cancer. Radionuclide bone scans and computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) supplement clinical and biochemical evaluations (prostate-specific antigen [PSA]) for suspected metastatic disease to bones and lymph nodes. There is no consensus about the use of imaging in the evaluation of local tumor recurrence. The use of ultrasound has been limited to biopsy guidance of the prostatic bed, or percutaneous biopsy of enlarged lymph nodes detected on CT or MRI. The use of MRI is evolving. Recent studies indicate that the use of MRI provides valuable information in the evaluation of local tumor recurrence, and nodal and bony metastases. In a patient post-radiation therapy, the method of combining MRI anatomic information with MR spectroscopic metabolic information is evolving. Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising.

Original languageEnglish (US)
Pages (from-to)616-634
Number of pages19
JournalSeminars in Oncology
Volume30
Issue number5
DOIs
StatePublished - Jan 1 2003

Fingerprint

Prostate-Specific Antigen
Magnetic Resonance Imaging
Prostatic Neoplasms
Lymph Nodes
Tomography
Biopsy
Recurrence
Neoplasms
Bone Diseases
Radioisotopes
Positron-Emission Tomography
Anatomy
Radiotherapy
Guidelines
Neoplasm Metastasis
Bone and Bones
Positron Emission Tomography Computed Tomography
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hricak, H., Schöder, H., Pucar, D., Lis, E., Eberhardt, S. C., Onyebuchi, C. N., & Scher, H. I. (2003). Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level. Seminars in Oncology, 30(5), 616-634. https://doi.org/10.1016/S0093-7754(03)00359-2

Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level. / Hricak, Hedvig; Schöder, Heiko; Pucar, Darko; Lis, Eric; Eberhardt, Steven C.; Onyebuchi, Chinyere N.; Scher, Howard I.

In: Seminars in Oncology, Vol. 30, No. 5, 01.01.2003, p. 616-634.

Research output: Contribution to journalArticle

Hricak, H, Schöder, H, Pucar, D, Lis, E, Eberhardt, SC, Onyebuchi, CN & Scher, HI 2003, 'Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level', Seminars in Oncology, vol. 30, no. 5, pp. 616-634. https://doi.org/10.1016/S0093-7754(03)00359-2
Hricak, Hedvig ; Schöder, Heiko ; Pucar, Darko ; Lis, Eric ; Eberhardt, Steven C. ; Onyebuchi, Chinyere N. ; Scher, Howard I. / Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level. In: Seminars in Oncology. 2003 ; Vol. 30, No. 5. pp. 616-634.
@article{bee9f167d4ee4f22ad043516e9e0e9f5,
title = "Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level",
abstract = "Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's needs. There are evidence-based guidelines for the use of imaging in assessing the presence of distant spread of prostate cancer. Radionuclide bone scans and computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) supplement clinical and biochemical evaluations (prostate-specific antigen [PSA]) for suspected metastatic disease to bones and lymph nodes. There is no consensus about the use of imaging in the evaluation of local tumor recurrence. The use of ultrasound has been limited to biopsy guidance of the prostatic bed, or percutaneous biopsy of enlarged lymph nodes detected on CT or MRI. The use of MRI is evolving. Recent studies indicate that the use of MRI provides valuable information in the evaluation of local tumor recurrence, and nodal and bony metastases. In a patient post-radiation therapy, the method of combining MRI anatomic information with MR spectroscopic metabolic information is evolving. Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising.",
author = "Hedvig Hricak and Heiko Sch{\"o}der and Darko Pucar and Eric Lis and Eberhardt, {Steven C.} and Onyebuchi, {Chinyere N.} and Scher, {Howard I.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S0093-7754(03)00359-2",
language = "English (US)",
volume = "30",
pages = "616--634",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Advances in Imaging in the Postoperative Patient with a Rising Prostate-Specific Antigen Level

AU - Hricak, Hedvig

AU - Schöder, Heiko

AU - Pucar, Darko

AU - Lis, Eric

AU - Eberhardt, Steven C.

AU - Onyebuchi, Chinyere N.

AU - Scher, Howard I.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's needs. There are evidence-based guidelines for the use of imaging in assessing the presence of distant spread of prostate cancer. Radionuclide bone scans and computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) supplement clinical and biochemical evaluations (prostate-specific antigen [PSA]) for suspected metastatic disease to bones and lymph nodes. There is no consensus about the use of imaging in the evaluation of local tumor recurrence. The use of ultrasound has been limited to biopsy guidance of the prostatic bed, or percutaneous biopsy of enlarged lymph nodes detected on CT or MRI. The use of MRI is evolving. Recent studies indicate that the use of MRI provides valuable information in the evaluation of local tumor recurrence, and nodal and bony metastases. In a patient post-radiation therapy, the method of combining MRI anatomic information with MR spectroscopic metabolic information is evolving. Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising.

AB - Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's needs. There are evidence-based guidelines for the use of imaging in assessing the presence of distant spread of prostate cancer. Radionuclide bone scans and computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET) supplement clinical and biochemical evaluations (prostate-specific antigen [PSA]) for suspected metastatic disease to bones and lymph nodes. There is no consensus about the use of imaging in the evaluation of local tumor recurrence. The use of ultrasound has been limited to biopsy guidance of the prostatic bed, or percutaneous biopsy of enlarged lymph nodes detected on CT or MRI. The use of MRI is evolving. Recent studies indicate that the use of MRI provides valuable information in the evaluation of local tumor recurrence, and nodal and bony metastases. In a patient post-radiation therapy, the method of combining MRI anatomic information with MR spectroscopic metabolic information is evolving. Another modality offering information about anatomy and metabolism of the local disease is PET/CT. The value of PET/CT at present is controversial, but new studies exploring the role of PET/CT in aggressive prostate cancer are promising.

UR - http://www.scopus.com/inward/record.url?scp=17144453160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144453160&partnerID=8YFLogxK

U2 - 10.1016/S0093-7754(03)00359-2

DO - 10.1016/S0093-7754(03)00359-2

M3 - Article

VL - 30

SP - 616

EP - 634

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5

ER -